All Stories

Gelesis, a Boston, MA-based clinical stage biotechnology company focused on the development of products to safely induce weight loss and improve glycemic control, closed a $31.5m growth financing round. Backers included Cormorant Asset Management, and current investors Invesco Asset Management,…

Axonics Modulation Technologies, Inc., an Irvine, CA-based developer of miniaturized implantable Sacral Neuromodulation technology, completed a $38.5m Series B financing. Backers included new investors Advent Life Sciences and Cormorant Asset Management, and existing investors Edmond de Rothschild Investment Partners, NeoMed…